GET DAILY SIGNALSSpyre Therapeutics (SYRE) and the +33% Potential to $135 Target
Key Takeaways
- The $135 price target represents the highest Wall Street target for SYRE, set by Deutsche Bank, implying approximately 33% upside from the current price near $101.50.
- Strong bullish factors include a unanimous analyst consensus rating of Strong Buy, a broad pipeline targeting multi-billion-dollar IBD markets, and significant institutional ownership above 90%.
- The biggest risks include binary clinical trial outcomes, ongoing cash burn with no product revenue, a high beta of 3.02 indicating extreme volatility, and a short float near 20% that signals meaningful bearish sentiment.
- The stock has already staged an extraordinary rally from a 52-week low of $14.51 to recent levels above $100, raising questions about how much upside remains priced in.
- Investors should monitor upcoming clinical data readouts, the August 4, 2026 earnings report, and any changes in analyst coverage as critical catalysts for the next directional move.
Why the $135 Price Target Stands Out
Among the 17 analysts covering SYRE, Deutsche Bank stands out with the most bullish 12-month price target of $135. That figure, reiterated in June 2026 when the firm raised its target from $115, represents the ceiling of Wall Street expectations for this clinical-stage biotechnology company. With the stock recently closing at $101.50, reaching $135 would require a gain of roughly 33% — a meaningful move that has captured the attention of growth-oriented biotech investors.
Understanding Spyre's Pipeline
Spyre Therapeutics is a clinical-stage biotechnology company focused on developing next-generation antibody therapeutics for inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, as well as rheumatic conditions. The company's pipeline includes SPY001, an anti-α4β7 monoclonal antibody in Phase 2 trials; SPY002 and SPY072, both anti-TL1A antibodies; and SPY003, which targets IL-23. Beyond single-agent programs, Spyre is advancing combination approaches — SPY120 (anti-α4β7 plus anti-TL1A), SPY130 (anti-α4β7 plus anti-IL-23), and SPY230 (anti-TL1A plus anti-IL-23) — that could differentiate it in a crowded immunology landscape. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Market Position and Recent Performance
SYRE has delivered one of the most dramatic biotech rallies of the past year. The stock has surged from a 52-week low of $14.51 to recent levels above $100, boosting its market capitalization to approximately $8.8 billion. The move reflects growing confidence in the company's pipeline and the enormous commercial opportunity in IBD, where established therapies still leave many patients underserved. However, investors should note that Spyre remains a pre-revenue company — its last reported earnings per share (EPS) came in at -$0.74, and the company is not expected to generate meaningful product sales in the near term. A price-to-book ratio of approximately 16.5 highlights the premium valuation the market has assigned to its pipeline promise.
Potential Catalysts for Growth
Several factors could propel Spyre Therapeutics toward Deutsche Bank's $135 target. Positive Phase 2 data for SPY001 or any of the combination programs would likely serve as the most powerful catalyst, potentially validating the company's approach to developing extended half-life antibodies for chronic inflammatory conditions. The IBD market represents a multi-billion-dollar commercial opportunity, and Spyre's combination strategy could position it to capture market share from established players if clinical data demonstrate superior efficacy.
Institutional conviction provides another tailwind. Over 90% of SYRE shares are held by institutions, and major ETFs including the SPDR S&P Biotech ETF (XBI) and iShares Biotechnology ETF (IBB) maintain exposure. Recent analyst activity has been overwhelmingly positive: Mizuho raised its target to $120 in July 2026, BTIG maintains a $112 target, and multiple firms have reiterated Buy ratings following the latest clinical updates.
Key Risks to Consider
The path to $135 faces substantial hurdles. As a clinical-stage biotech, Spyre carries binary risk: disappointing trial results could trigger sharp reversals. The stock's 3.02 beta underscores its extreme sensitivity to both company-specific news and broader market sentiment. A short float near 20% indicates that a significant portion of market participants are betting against the stock, which can amplify both upside squeezes and downside pressure.
Cash burn remains a persistent concern. With no approved products generating revenue, Spyre funds operations through capital markets — a reality that introduces dilution risk for existing shareholders. The company has already increased its share count by nearly 30% in the past year, and further equity raises could weigh on per-share valuation. Competitive pressure from larger immunology players with established commercial infrastructures and deeper pipelines also cannot be ignored.
Wall Street Consensus and Targets
The analyst community overwhelmingly favors SYRE, with 16 of 17 analysts rating the stock Strong Buy or Buy and only one dissenting voice. The average 12-month price target sits near $105.79, just modestly above current levels. Targets span from a low of $78 to Deutsche Bank's high of $135, reflecting genuine disagreement about how much of the pipeline's potential is already priced in. Notably, Mizuho's $120 target and BTIG's $112 suggest that even more conservative bullish analysts see room for double-digit percentage gains. The wide spread between the low and high targets — roughly $57 — signals unusually high uncertainty, typical for a clinical-stage biotech whose valuation hinges on future trial results rather than current fundamentals.
Technical Analysis Snapshot
From a technical perspective, SYRE currently trades just below its 52-week high of $105.09. A breakout above that level would establish a new all-time high and could open a path toward the psychologically important $120 and $135 zones. The stock's 200-day moving average sits near $56, reflecting how far and how fast the rally has extended. Key support levels to watch include the $80–$85 region, which aligns with the lower end of analyst targets and previous consolidation zones. A failure to hold above $90 on any significant pullback could signal a broader trend shift. I also reviewed this setup using Tickeron’s AI Trend Prediction Engine to get an additional perspective on momentum.
Final Thoughts
The $135 price target for Spyre Therapeutics is ambitious but not implausible. Achieving it would likely require positive clinical data from SPY001 or one of the combination programs, continued analyst support, and a favorable macro environment for high-beta biotech names. The strength of institutional backing and the enthusiastic analyst consensus provide a solid foundation, but the stock's pre-revenue status, ongoing cash burn, and binary clinical risk mean the journey is far from assured. Investors should watch upcoming trial data readouts, the August 4 earnings report for pipeline updates, and whether SYRE can decisively break above its 52-week high near $105 as an early technical signal. While the target remains within reach based on current Wall Street modeling, the wide range of analyst estimates underscores the reality that outcomes — both positive and negative — can diverge sharply from consensus expectations in clinical-stage biotechnology.
Using AI Daily Buy/Sell Signals for Biotech Stocks
In my research process, I have found Tickeron's AI Daily Buy/Sell Signals to be a practical way to monitor high-volatility names like SYRE. The tool applies artificial intelligence to scan thousands of stocks and ETFs, delivering Buy, Sell, or Hold signals based on technical patterns and market conditions. This helps me stay on top of developments without relying solely on manual chart review.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Disclaimers and LimitationsSYRE's RSI Oscillator leaves overbought zone
The 10-day RSI Indicator for SYRE moved out of overbought territory on November 10, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 instances where the indicator moved out of the overbought zone. In 24 of the 27 cases the stock moved lower in the days that followed. This puts the odds of a move down at 89%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 14 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SYRE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
SYRE broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on SYRE as a result. In 65 of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.
The Moving Average Convergence Divergence (MACD) for SYRE just turned positive on October 20, 2026. Looking at past instances where SYRE's MACD turned positive, the stock continued to rise in 35 of 41 cases over the following month. The odds of a continued upward trend are 85%.
SYRE moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for SYRE crossed bullishly above the 50-day moving average on October 29, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +12.85% 3-day Advance, the price is estimated to grow further. Considering data from situations where SYRE advanced for three days, in 261 of 300 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
The Aroon Indicator entered an Uptrend today. In 148 of 174 cases where SYRE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 85%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.592) is normal, around the industry mean (3.498). P/E Ratio (-54.111) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (526.316) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. SYRE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 54 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SYRE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biopharmaceutical company
Industry Biotechnology
Advertisement